Mastering Pharmacotherapy Management of Type 2 Diabetes
(4)
Image For Activity Cover
Availability
On-Demand
4 Courses
Expires on Dec 31, 2024
Cost
$0.00
Credit Offered
4 AMA PRA Category 1 Credits
4 ABIM-MOC Points
4 Participation Credits
  • Course Description
  • Target Audience
  • Learning Objectives
  • Accreditation Statement
  • Faculty and Disclosures
  • Recommended
This multi-modular course provides learners with a history and overview of T2D pharmacotherapy and the role of the endocrinologist, focus on newer TD pharmacotherapies, T2D and cardiovasuclar disease, and T2D and obesity.
The intended audience for this activity is endocrinologists who treat type 2 diabetes (T2D) in the United States.
1. Discuss the current status of T2D pharmacotherapy management, including guidelines, prescription trends and clinical inertia, and the role of the endocrinologist.

2. Evaluate current & emerging medications, with a focus on safety, efficacy, and mechanisms of action of newer drug classes.

3. Apply decision-making strategies for therapy optimization when patients present with T2D and cardiovascular disease and/or obesity.

The Endocrine Society is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. Endocrine Society has achieved Accreditation with Commendation.

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the the Endocrine Society. The Endocrine Society is accredited by the ACCME to provide continuing medical education for physicians. 

AMA PRA Category 1 Credit

The Endocrine Society designates each activity in this course for a maximum of 4.00 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. While offering CME credits noted above, this program is not intended to provide extensive training or certification in the field.


Please note that while other accrediting bodies accept AMA PRA Category 1 credit, we can only award and report this credit for MDs/DOs. For those outside of this accreditation, please complete the participation evaluation and use that certificate as proof of attendance to submit to your accrediting body.


Maintenance of Certification (MOC)
Successful completion of each CME activity in this course, which includes participation in the evaluation component, enables the participant to earn up to 1.50 points in the American Board of Internal Medicine (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.


For questions about content or obtaining CME credit, please contact the Endocrine Society at info@endocrine.org

Jennifer Green, MD - Program Chair
Professor of Medicine
Duke Department of Medicine

Nicole Ehrhardt, MD

Assistant Professor of Medicine
University of Washington

Neha Pagidipati, MD, MPH
Assistant Professor of Medicine and Cardiovascular Disease
Duke University of Medicine

Robert Kushner, MD
Professor of Medicine
Northwestern Medicine

Marcelo Correia, MD, MSc, PhD
Clinical Assistant Professor
University of Iowa


STATEMENT OF INDEPENDENCE
As a provider of CME accredited by the Accreditation Council for Continuing Medical Education, the Endocrine Society has a policy of ensuring that the content and quality of this educational activity are balanced, independent, objective, and scientifically rigorous. The scientific content of this activity was developed under the supervision of the Endocrine Society’s peer reviewers.

DISCLOSURE POLICY
The faculty, committee members, and staff who are in position to control the content of this activity are required to disclose to the Endocrine Society and to learners any relevant financial relationship(s) of the individual that have occurred within the last 12 months with any commercial interest(s) whose products or services are related to the content. Financial relationships are defined by remuneration in any amount from the commercial interest(s) in the form of grants; research support; consulting fees; salary; ownership interest (e.g., stocks, stock options, or ownership interest excluding diversified mutual funds); honoraria or other payments for participation in speakers' bureaus, advisory boards, or boards of directors; or other financial benefits. The intent of this disclosure is not to prevent planners with relevant financial relationships from planning or delivery of content, but rather to provide learners with information that allows them to make their own judgments of whether these financial relationships may have influenced the educational activity with regard to exposition or conclusion.

The Endocrine Society has reviewed these relationships to determine which are relevant to the content of this activity and resolved any identified conflicts of interest for these individuals.

The faculty reported the following relevant financial relationship(s) during the content development process for this activity:

Jennifer Green, MD: Boehringer Ingelheim/Lilly; Consultant; NovoNordisk; Consultant; AstraZeneca; Consultant; Jaeb Center for Health Research; DSMB member, NIDDK APS trial consortium; American Diabetes Association; Associate Editor, Diabetes Care; Pfizer; Consultant; Bayer; Consultant; Sanofi; Consultant; Anji; Consultant; Valo; Consultant; Vertex; Consultant; Merck; Consultant;
The following companies/organizations provide funds to my institution for the conduct of clinical
research: these funds in part support my salary: Boehringer Ingelheim/Lilly; Merck; Roche NIDDK

Nicole Ehrhardt, MD: Novonordisk advisory board; Dexcom advisory board; Dexcom investigator initiated research; Novonordisk and Merck Educational Grants

Robert Kushner, MD: Novo Nordisk, Advisory Board, Weight Watchers, Advisory Board, Pfizer, Consultant, Lilly, Advisory Board, Boehringer Ingelheim, Advisory Board, Altimmune, consultant,

Marcelo Correia, MD, PhD: Principal investigator for the following pharmaceutical companies and receive research grants from: Novartis, Eli Lilly, Novo Nordisk.
Novo Nordisk, consultant, received compensation for one consulting service in 2021. Research grant from Stead Family (Iowa)

Neha Pagidipati, MD: Research support from Alnylam, Amgen, Boehringer Ingelheim, Eggland’s Best, Eli Lilly, Novartis, Novo Nordisk, Verily Life Sciences; Consultation/Advisory Panels for Bayer, Boehringer Ingelheim, CRISPR Therapeutics, Eli Lilly, Esperion, AstraZeneca, Merck, Novartis, and Novo Nordisk; Executive Committee member for trials sponsored by Novo Nordisk and by Amgen; Medical advisory board for Miga Health 


The following committee member who planned and reviewed content for this activity reported relevant financial relationships: 
Beret Casey, MD

The Endocrine Society staff involved in the development of this CME activity reported no relevant financial relationships.

The Endocrine Society staff have reviewed all disclosures and resolved or managed all relevant identified conflicts of interest, as applicable.

Acknowledgement of Commercial Support:
This educational activity is supported by an educational grant from Lilly
   
     EndoCareers | Contact Us | Privacy Policy | Terms of Use CONNECT WITH US                
       © 2021 Copyright Endocrine Society. All rights reserved.
2055 L Street NW, Suite 600 | Washington, DC 20036      
 202.971.3636 | 888.363.6274
      
   
Android App Download IOS App Download Powered By